Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00007774 · ClinicalTrials.gov registry record · Phase 4
To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
A Phase 4 study, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 4
- Development phase
- 600
- Enrollment target
NCT00007774 is a Phase 4 study that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 600 participants.
The verdict
NCT00007774, a Phase 4 study, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 600 participants
- Enrollment target
Study Summary
Although currently marketed antipsychotic drugs are useful in the treatment of schizophrenia, efficacy and safety profiles need to be improved. Forty to eighty percent of patients either fail to respond or only partially respond to conventional antipsychotic agents. Secondary symptoms may be unimproved even in patients who respond to treatment. A variety of adverse events occur in patients receiving currently available agents. The severity of these events contributes to the poor compliance that is observed in this patient population. Olanzapine is a novel antipsychotic agent with a reduced incidence of extrapyramidal symptoms. Other side effects are minimal.
Interventions
- DRUG Haloperidol
- DRUG Olanzapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 1998-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00007774
The ClinicalTrials.gov registry entry for NCT00007774 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Haloperidol is the first listed.
NCT00007774 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00007774 about?
NCT00007774 is a clinical study titled "To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia". Although currently marketed antipsychotic drugs are useful in the treatment of schizophrenia, efficacy and safety profiles need to be improved. Forty to eighty percent of patients either fail to respond or only partially respond to conventional antipsychotic agents. Secondary symptoms may be unimpro...
What is the current status of trial NCT00007774?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 600 participants. The study started on 1998-03.
What interventions are being tested in trial NCT00007774?
The interventions under investigation include: Haloperidol (DRUG), Olanzapine (DRUG).
Who is sponsoring clinical trial NCT00007774?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.